ENGN
enGene Therapeutics Inc.
$1.92
+0.01 (+0.52%)
At close · Jul 7
Market Cap
$128.62M
Shares
66,989,466
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$117.3M
-112.7%
FY2025
Diluted EPS
$2.29
+56.8%
FY2025
Operating Cash Flow
-$99.24M
-105.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $98.75M | $94.48M | $38.32M | $16.46M | $15.47M | |
| $33.83M | $28.69M | $23.98M | $9.6M | $3.96M | |
| $687K | $500K | $300K | $200K | $200K | |
| $132.58M | $123.17M | $62.3M | $26.06M | $19.43M | |
| -$132.58M | -$123.17M | -$62.3M | -$26.06M | -$19.43M | |
| $2.99M | $2.99M | $2.8M | $4.95M | $1.42M | |
| $9.61M | $9.43M | $10.41M | $1.12M | $129K | |
| $5.47M | $5.86M | $7.14M | -$73.84M | -$5.01M | |
| -$127.11M | -$117.3M | -$55.16M | -$99.9M | -$24.44M | |
| -$258K | $0 | -$19K | $17K | $22K | |
| -$126.85M | -$117.3M | -$55.14M | -$99.92M | -$24.46M | |
| -$126.85M | -$117.3M | -$55.14M | -$104.74M | -$29.02M | |
| -$127.02M | -$116.77M | -$54.74M | -$99.92M | -$23.3M | |
| USD/shares | — | $2.29 | $1.46 | $151.22 | $44.30 |
| USD/shares | — | $2.29 | $1.46 | $151.22 | $44.30 |
| shares | — | 51.12M | 37.78M | 692.61K | 655.15K |
| shares | — | 51.12M | 37.78M | 692.61K | 655.15K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
0.82×
Biotechnology median 7.60×